Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 121.1B, Vertex Pharmaceuticals(VRTX) trades at $476.17. The stock has a price-to-earnings ratio of 31.12.
As of 2026-02-21, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $465.00 and $479.12. The current price stands at $476.17, placing the stock +2.4% above today's low and -0.6% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 941.24K, compared to an average daily volume of 1.77M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Key Points Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitab...
Vertex Pharmaceuticals (NasdaqGS:VRTX) and CRISPR Therapeutics are ramping up patient treatments with Casgevy, a gene-editing therapy. Casgevy is approved for...
Key Points Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval...
Analyst ratings
73%
of 33 ratingsMore VRTX News
Morgan Stanley raised the firm’s price target on Crispr Therapeutics (CRSP) to $33 from $32 and keeps an Underweight rating on the shares. The firm refreshed it...
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $591 from $518 and keeps a Buy rating on the shares. The...
Vertex Pharmaceuticals reported full-year 2025 results showing revenue of US$12.00 billion, up from US$11.02 billion a year earlier, with net income of US$3.95...
If you are wondering whether Vertex Pharmaceuticals at around US$491.47 is still a sensible entry or hold, the starting point is understanding what you are actu...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.